Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Moody

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Problems in Diagnostic Radiology|October 11, 2024
Improving access to outpatient computed tomographyDenes Szekeres, Michael Lechner, Susan Moody, et al.
Molecular Cancer Therapeutics|August 24, 2019
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant CancersHuai-Xiang Hao, Hongyun Wang, Chen Liu, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Nature Communications|January 27, 2025
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancerVeronica Rendo, Michael Schubert, Nicholas Khuu, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Problems in Diagnostic Radiology|October 11, 2024
Improving access to outpatient computed tomographyDenes Szekeres, Michael Lechner, Susan Moody, et al.
Molecular Cancer Therapeutics|August 24, 2019
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant CancersHuai-Xiang Hao, Hongyun Wang, Chen Liu, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Nature Communications|January 27, 2025
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancerVeronica Rendo, Michael Schubert, Nicholas Khuu, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Pageof 1